# Y2 Receptor Agonism in Multi-Receptor Obesity Drugs

Canonical source: https://retacompare.com/research/y2-receptor-agonism-in-multi-receptor-obesity-drugs

Receptor Combinations · 2026-05-02


    This article explores the integration of long-acting Y2 receptor agonists into next-generation multi-receptor obesity therapies, highlighting their potential role in enhancing metabolic outcomes alongside established agents like Retatrutide.

The big picture

The landscape of obesity and metabolic disorder treatments is evolving, particularly following the promising data surrounding Retatrutide (LY3437943), a triple agonist targeting GLP-1, GIP, and glucagon receptors. While Retatrutide is still in Phase 3 clinical trials and has not yet received regulatory approval, it sets a precedent for the exploration of multi-agonist therapies. The next wave of research is increasingly focusing on the incorporation of Y2 receptor agonism into quad-agonist designs, aiming to leverage the synergistic effects of multiple pathways to optimize weight loss and metabolic health.

How it works

The Y2 receptor (Y2R), a member of the neuropeptide Y receptor family, plays a critical role in appetite regulation and energy homeostasis. Agonism of Y2R is hypothesized to enhance the satiety signals in the brain, potentially leading to reduced food intake. By combining Y2 receptor agonists with existing pathways targeted by GLP-1 and GIP, researchers aim to create a more comprehensive approach to obesity treatment. The rationale for this combination lies in the complementary mechanisms of action—while GLP-1 and GIP influence insulin secretion and appetite, Y2R agonism could further modulate energy balance and metabolic rate.

Key points at a glance

Retatrutide is a triple agonist currently in Phase 3 trials, targeting GLP-1, GIP, and glucagon.

Y2 receptor agonism is being explored for its potential to enhance satiety and reduce food intake.

Quad-agonist designs are still in early development, with no approved therapies combining four or more pathways.

Companies such as Hanmi and Amgen are investigating combinations that include Y2 agonists.

Long-acting formulations of Y2 agonists could improve patient compliance and therapeutic outcomes.

Multi-receptor approaches may offer improved efficacy compared to mono- or dual-agonist therapies.

Where this fits in the pipeline

Currently, several programs are investigating Y2 receptor agonists in combination with other metabolic agents. Notable candidates include HM15275 from Hanmi and MariTide (AMG 133) from Amgen. While these are still in early clinical stages, their potential to enhance the effects of existing therapies like Tirzepatide and Semaglutide is being closely monitored. As of now, no quad-agonist or penta-agonist therapy has received approval, and most remain in preclinical or early clinical trials.

What it could mean for patients

If successful, the integration of Y2 receptor agonism into multi-receptor therapies could lead to more effective treatments for obesity and metabolic disorders. Enhanced satiety signals and improved energy regulation may result in greater weight loss and better metabolic health outcomes for patients. However, the clinical impact remains theoretical until more data from ongoing studies become available.

Open questions and what we don't yet know

Despite the promise of Y2 receptor agonism, several uncertainties persist. The specific mechanisms by which Y2 agonists will interact with other pathways are not fully understood, and risks associated with multi-receptor targeting must be carefully evaluated. Additionally, regulatory challenges and the engineering of stable, long-acting formulations present further hurdles that need to be addressed before these therapies can reach the market.

Bottom line

The exploration of Y2 receptor agonism in multi-receptor obesity therapies represents a forward-looking approach in metabolic drug development, building on the foundations laid by agents like Retatrutide. Continued research will be crucial in determining the viability and effectiveness of these combinations.

This article is research-only educational content and is not medical advice. None of the drugs discussed are approved as quad-agonists or penta-agonists at the time of writing.

## Sources